<SEC-DOCUMENT>0001104659-25-078643.txt : 20250814
<SEC-HEADER>0001104659-25-078643.hdr.sgml : 20250814
<ACCEPTANCE-DATETIME>20250814162009
ACCESSION NUMBER:		0001104659-25-078643
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250814
DATE AS OF CHANGE:		20250814

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ProMIS Neurosciences Inc.
		CENTRAL INDEX KEY:			0001374339
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93797
		FILM NUMBER:		251219564

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 200, 1920 YONGE STREET
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M4S 3E2
		BUSINESS PHONE:		416-847-6898

	MAIL ADDRESS:	
		STREET 1:		SUITE 200, 1920 YONGE STREET
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M4S 3E2

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMORFIX LIFE SCIENCES LTD
		DATE OF NAME CHANGE:	20060831

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GORDON MICHAEL S
		CENTRAL INDEX KEY:			0001034608
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	MAIL ADDRESS:	
		STREET 1:		C/O VINIK ASSET MANAGEMENT LP
		STREET 2:		260 FRANKLIN STREET, SUITE 1900
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: GORDON MICHAEL S -->
          <cik>0001034608</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>4</amendmentNo>
      <securitiesClassTitle>Common Shares, No Par Value</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>06/30/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001374339</issuerCik>
        <issuerName>ProMIS Neurosciences Inc.</issuerName>
        <issuerCusip>74346M406</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>Suite 200, 1920 Yonge Street</com:street1>
          <com:city>Toronto</com:city>
          <com:stateOrCountry>A6</com:stateOrCountry>
          <com:zipCode>M4S 3E2</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Michael S. Gordon</reportingPersonName>
      <memberGroup>a</memberGroup>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>4886108.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>4886108.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4886108.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.0</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>This Amendment No. 4 to Schedule 13G is filed jointly on behalf of Michael S. Gordon and Title 19 Promis, a series of a Delaware limited liability company ("Title 19 Promis," and collectively with Mr. Gordon, the "Reporting Persons"), pursuant to Rule 13d-1(c). Prior to the effective date of the registration of the Issuer's common shares, no par value per share ("Common Shares"), pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, in July of 2022, (i) Title 19 Acies, a series of a Delaware limited liability company ("Title 19 Acies"), acquired 2,900,000 Common Shares, representing 48,333 Common Shares following a 60:1 stock split (the "Stock Split") of the Issuer that occurred in June 2022 and (ii) Title 19 Promis acquired (a) 12,375,000 Common Shares, representing 206,250 Common Shares following the Stock Split (such 206,250 Common Shares, the "August 2021 Common Shares"), (b) 3,093,750 warrants to purchase Common Shares, each initially exercisable to purchase one Common Share and, as a result of the Stock Split, now exercisable to purchase an aggregate of 51,562 Common Shares ("March 2022 Warrant Shares") and (c) 30,000,000 Series 1 Preferred Shares ("Series 1 Preferred Shares") of the Issuer, each initially convertible into one Common Share in accordance with the terms of the Series 1 Preferred Shares and, as a result of the Stock Split, became convertible into an aggregate of 500,000 Common Shares.

On October 11, 2022, Title 19 Promis acquired 106,391 Common Shares (the "October 2022 Common Shares") and 26,597 warrants, each exercisable to purchase one Common Share (such 26,597 Common Shares underlying such warrants, the "October 2022 Warrant Shares"), in a private placement conducted by the Issuer. On August 23, 2023, Title 19 Promis acquired 797,872 common share units, each consisting of one Common Share (such 797,872 Common Shares, the "August 2023 Common Shares") and one warrant to purchase one Common Share (the "August 2023 Warrants," and such 797,972 Common Shares underlying the August 2023 Warrants, the "August 2023 Warrant Shares"), in a private placement conducted by the Issuer. The August 2023 Warrants have an exercise price of $1.75 per whole warrant, are currently exercisable and expire February 23, 2029.

On December 4, 2023, the Issuer entered into a Share Exchange Agreement with the holders of the Issuer's Series 1 Preferred Shares, pursuant to which the Series 1 Preferred Shares were exchanged for a new class of Series 2 convertible preferred shares (the "Series 2 Preferred Shares"), effected on a 60:1 basis to reflect the Stock Split, such that the Series 1 Preferred Shares held by Title 19 Promis were exchanged for 500,000 Series 2 Preferred Shares (the "Title 19 Series 2 Preferred Shares"), each convertible into one Common Share in accordance with the terms of the Series 2 Preferred Shares.

On July 31, 2024, Title 19 Promis acquired (A) 465,116 Common Shares (the "July 2024 Common Shares"), (B) 465,116 Tranche A Common Share purchase warrants (the "July 2024 Tranche A Warrants"), (C) 465,116 Tranche B Common Share purchase warrants (the "July 2024 Tranche B Warrants") and (D) 465,116 Tranche C Common Share purchase warrants (the "July 2024 Tranche C Warrants"), in a private placement (the "July 2024 Offering") conducted by the Issuer. Upon the closing of the July 2024 Offering, which was a cumulative qualified equity financing in excess of $14 million, the Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio, such that the Title 19 Series 2 Preferred Share converted into 500,000 Common Shares (the "Conversion Shares").

On September 16, 2024 and September 17, 2024, Mr. Gordon acquired an aggregate of 93,223 Common Shares (the "Open Market Shares") on the open market.

On March 13, 2025, the ownership of Title 19 Acies was assigned to Skye Peak Partners LLC, a Delaware limited liability company ("SPP"), effective as of January 1, 2025. In connection with such assignment, the management of Title 19 Acies changed from Mr. Gordon as sole manager to Emmett Gordon and Michael Youniss as managers, and Mr. Gordon does not otherwise have investment control over the shares of the Issuer held by SPP. Accordingly, Mr. Gordon no longer has a pecuniary interest in or beneficial ownership of shares of the Issuer held by Title 19 Acies.

On June 30, 2025, Mr. Gordon contributed the Open Market Shares of the Issuer held by Mr. Gordon to SPP in exchange for membership interests of SPP.

On July 25, 2025, Title 19 Promis:

(i) exercised 119,800 July 2024 Tranche A Warrants, each exercisable to purchase one Common Share, and acquired 119,800 Common Shares (the "July 2024 Tranche A Warrant Shares");

(ii) exercised 119,800 July 2024 Tranche B Warrants, each exercisable to purchase one Common Share, and acquired 119,800 Common Shares (the "July 2024 Tranche B Warrant Shares"); and

(iii) exercised 119,800 July 2024 Tranche C Warrants, each exercisable to purchase one Common Share, and acquired 119,800 Common Shares (the "July 2024 Tranche C Warrant Shares").

These July 2024 Tranche A Warrants, July 2024 Tranche B Warrants and July 2024 Tranche C Warrants were exercisable at an exercise price of $2.02, $2.02 and $2.50 per warrant share, respectively; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of the July 2024 Tranche A Warrants, July 2024 Tranche B Warrants and July 2024 Tranche C Warrants are currently exercisable and expire:

(a) in the case of the July 2024 Tranche A Warrants, on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310;

(b) in the case of the July 2024 Tranche B Warrants, on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310; and

(c) in the case of the July 2024 Tranche C Warrants, on July 31, 2029.

On July 29, 2025, Title 19 Promis acquired 539,100 warrants (the "July 2025 Warrants"), each exercisable to purchase one Common Share (such 539,100 Common Shares, the "July 2025 Warrant Shares"), at an exercise price of $1.25 per share. The purchase price for each July 2025 Warrant was $0.1875 per share. The July 2025 Warrants are currently exercisable and expire five years after the date of issuance.

The acquisition of the July 2024 Tranche A Common Shares, the July 2024 Tranche B Common Shares and the July 2024 Tranche C Common Shares and the Common Shares underlying the July 2025 Warrants being deemed beneficially owned by Mr. Gordon due to the July 2025 Warrants being currently exercisable, when added to all other acquisitions of securities of the same class during the 12 months immediately preceding the date of such acquisition, aggregates to greater than two percent (2%) of the class of such securities. However, such acquisition was not done with any purpose, or with the effect, of changing or influencing the control of the Issuer, or in connection with or as a participant in any transaction having that purpose or effect. Accordingly, the Reporting Persons are filing this Amendment No. 4 to Schedule 13G pursuant to Rule 13d-1(c).</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Title 19 Promis</reportingPersonName>
      <memberGroup>a</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>4886108.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>4886108.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4886108.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.0</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>See comments above.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>ProMIS Neurosciences Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>Suite 200, 1920 Yonge Street, Toronto, Ontario, M4S 3E2, Canada</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>This statement is filed by the Reporting Persons.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>The address of the Reporting Persons is c/o Trove, 40 Broad Street, 8th Floor, Boston, MA 02109.</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Mr. Gordon is a citizen of the United States of America. Title 19 Promis is a series of a Delaware limited liability company.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>4,886,108 for each of Mr. Gordon and Title 19 Promis consisting of (i) the August 2021 Common Shares, (ii) the March 2022 Warrant Shares, (iii) the October 2022 Common Shares, (iv) the August 2023 Common Shares, (v) the Conversion Shares, (vi) the October 2022 Warrant Shares, (vii) the August 2023 Warrant Shares, (viii) the July 2024 Common Shares, (ix) the July 2024 Tranche A Warrant Shares, (x) the July 2024 Tranche B Warrant Shares, (xi) the July 2024 Tranche C Warrant Shares, (xii) 345,316 Common Shares underlying the remaining July 2024 Tranche A Warrants, (xiii) 345,316 Common Shares underlying the remaining July 2024 Tranche B Warrants, (xiv) 345,316 Common Shares underlying the remaining July 2024 Tranche C Warrants and (xv) the July 2025 Warrant Shares. Mr. Gordon is the sole manager of Title 19 Promis.</amountBeneficiallyOwned>
        <classPercent>9.0% for each of Mr. Gordon and Title 19 Promis. The percentage of beneficial ownership is based upon 51,806,497 Common Shares outstanding as of August 13, 2025, plus (i) the March 2022 Warrant Shares, (ii) the October 2022 Warrant Shares, (iii) the August 2023 Warrant Shares, (iv) 345,316 Common Shares underlying the remaining July 2024 Tranche A Warrants, (v) 345,316 Common Shares underlying the remaining July 2024 Tranche B Warrants, (vi) 345,316 Common Shares underlying the remaining July 2024 Tranche C Warrants and (vii) the July 2025 Warrant Shares.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>0 for each of Mr. Gordon and Title 19 Promis.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>4,886,108 for each of Mr. Gordon and Title 19 Promis.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>0 for each of Mr. Gordon and Title 19 Promis.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>4,886,108 for each of Mr. Gordon and Title 19 Promis.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>N</notApplicableFlag>
        <identificationAndClassificationOfGroupMembers>See Exhibit A to Exhibit 99.1.</identificationAndClassificationOfGroupMembers>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <exhibitInfo>Joint Filing Agreement</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>Michael S. Gordon</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Michael S. Gordon</signature>
        <title>Self</title>
        <date>08/14/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Title 19 Promis</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Michael S. Gordon</signature>
        <title>Michael S. Gordon, Manager</title>
        <date>08/14/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2523440d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>JOINT FILING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act
of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including
the amendments thereto, the &ldquo;<U>13G</U>&rdquo;) with respect to the common shares, no par value per share, of ProMIS Neurosciences
Inc., a Canadian corporation. This Joint Filing Agreement shall be filed as an Exhibit to the 13G or any amendment thereto. The undersigned
acknowledge that each shall be responsible for the timely filing of any amendments to such joint filing and for the completeness and accuracy
of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information
concerning the others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Joint Filing Agreement may be executed in any number of counterparts,
each of which shall be deemed an original, but all of which, taken together, shall constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EXECUTED as of this 14<FONT STYLE="font-size: 10pt"><SUP>th </SUP></FONT>day
of August, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 97%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.75pt solid">/s/ Michael S. Gordon</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Michael S. Gordon</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><B>TITLE 19 PROMIS</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%">By:</TD>
    <TD STYLE="width: 91%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.75pt solid">/s/ Michael S. Gordon</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name: Michael S. Gordon</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Title: Manager</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit A </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">1.</TD>
    <TD>Michael S. Gordon </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">2.</TD>
    <TD>Title 19 Promis</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
